Antibiotics in the Intensive Care Unit: Focus on Agents for Resistant Pathogens

Emergency Medicine Clinics of North America

Volumn 26, Issue 3, 2008, Pages 813-834

  Volles, David F ^a   Branan, Trisha N ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIPHENHYDRAMINE; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; HYDROXYZINE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ATROPHY; BACTERIAL MENINGITIS; BONE MARROW SUPPRESSION; BURN; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DRUG HYPERSENSITIVITY; EDEMA; ERYTHROCYTE COUNT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOCRIT; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; INFLAMMATION; INTENSIVE CARE UNIT; LIVER FUNCTION TEST; LOADING DRUG DOSE; MYALGIA; NAUSEA; NECROTIZING FASCIITIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PERITONITIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK FACTOR; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; UREMIA; URINARY TRACT INFECTION; VOMITING;

EID: 48949118949     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2008.04.006     Document Type: Review

References (65)

1. Eggimann P., and Pittet D. Infection control in the ICU. Chest 120 6 (2001) 2059-2093
2. Weber D.J., Raasch R., and Rutala W.A. Nosocomial infections in the ICU. Chest 15 3 (1999) 35s-41s
3. Jones M.E., Draghi D.C., Thornsberry C., et al. Emerging resistance among bacterial pathogens in the intensive care unit: a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 3 14 (2004) 1-11
4. CDC NNIS System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
5. Karam G.H., and Heffner J.E. Emerging issues in antibiotic resistance in blood-borne infections. Am J Respir Crit Care Med 162 (2000) 1610-1616
6. Esposito S., and Leone S. Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 29 (2007) 494-500
7. Nicasio A.M., Kuti J.L., and Nicolau D.P. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 28 2 (2008) 235-249
8. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 22 (1996) 387-394
9. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
10. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
11. Paterson D.L., and Rice L.B. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?. Clin Infect Dis 36 (2003) 1006-1012
12. Talbot G.H., Bradley J., Edwards J.E., et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
13. Fridkin S.K., and Gaynes R.P. Antimicrobial resistance in intensive care units. Clin Chest Med 20 2 (1999) 303-316
14. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution to indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162 (2000) 505-511
15. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296-327
16. Niederman M.S., and Craven D.E. ATS/IDSA Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
17. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006) 1589-1596
18. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290 (2003) 2588-2598
19. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis Cochrane Database Syst Rev 2006;25(1):CD003344.
20. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27.
21. Burgess D.S. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115 (1999) 19s-23s
22. Levison M.E. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 18 (2004) 451-465
23. Scheetz M.H., Hurt K.M., Noskin G.A., et al. Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am J Health Syst Pharm 63 (2006) 1346-1360
24. Eagye K.J., Nicolau D.P., Lockhart S.R., et al. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Ann Clin Microbiol Antimicrob 6 (2007) 11. http://www.ann-clinmicrob.com/content/6/1/11 Accessed January 15, 2008
25. Wilhelm M., and Estes L. Vancomycin. Mayo Clin Proc 74 (1999) 928-935
26. Levine D. Vancomycin: a History. Clin Infect Dis 42 (2006) S5-S12
27. Maclayton D., and Hall R. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 41 (2007) 235-244
28. Rybak M. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 (2006) S35-S39
29. Micek S. Alternatives to Vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis 45 (2007) S184-S190
30. Meka V., and Gold H. Antimicrobial resistance to linezolid. Clin Infect Dis 39 (2004) 1010-1015
31. Perry C., and Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 61 (2001) 525-551
32. Eliopoulos G. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36 (2003) 473-481
33. Hair P., and Keam S. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and staphylococcus aureus bacteraemia. Drugs 67 (2007) 1483-1512
34. Ziglam H. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 8 14 (2007) 2279-2292
35. Fenton C., Keating G., and Curran M. Daptomycin. Drugs 64 (2004) 445-455
36. Lamp K., Friedrich L., Mendez-Vigo L., et al. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 120 (2007) S13-S20
37. Lamb H., Figgitt D., and Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58 (1999) 1061-1097
38. Hershberger E., Donabedian S., Konstantinou K., et al. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 38 (2004) 92-98
39. Kallel H., Bahloul M., Hergafi L., et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28 (2006) 366-369
40. Michalopoulos A.S., Tsiodras S., Rellos K., et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11 (2005) 115-121
41. Berlana D., Llop J.M., Fort E., et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 62 (2005) 39-47
42. Gilad J., and Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs 68 2 (2008) 165-189
43. Li J., Nation R.L., Turnidge J.D., et al. Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 6 9 (2006) 589-601
44. Zapantis A., Lopez M., Hoffman E., et al. The use of colistin in multidrug-resistant infections. Hosp Pharm 42 (2007) 1127-1138
45. Fraise A.P. Tigecycline: The answer to the beta-lactam and fluoroquinolone resistance?. J Infect 53 5 (2006) 293-300
46. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 25 3 (2005) 185-192
47. Livermore D.M. Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56 4 (2005) 611-614
48. Hurst M., and Lamb H.M. Meropenem: a review of its use in patients in intensive care. Drugs 59 3 (2000) 653-680
49. Zhanel G.G., Wiebe R., Dilay L., et al. Comparitive review of the carbapenems. Drugs 67 7 (2007) 1027-1052
50. Hellinger W.C., and Brewer N.S. Symposium on antimicrobial agents part VII. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 74 (1999) 420-434
51. Jones R.N., Huynh H.K., Biedenbach D.J., et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 54 (2004) 144-154
52. Lomaestro B.M., Tobin E.H., Shang W., et al. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 43 (2006) 26-28
53. Wright A.J. Symposium on antimicrobial agents-Part VI. The penicillins. Mayo Clin Proc 74 (1999) 290-307
54. Chambers H.F. Penicillins. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th edition (2005), Elsevier, Philadelphia 281-293
55. Lodise Jr. T.P., Lomaestro B., and Drusano G.L. Piperacillin-tazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44 (2007) 357-363
56. Hooper D.C. Quinolones. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th edition (2005), Elsevier, Philadelphia 451-473
57. Walker R.C. Symposium on antimicrobial agents part XIII. The fluoroquinolones. Mayo Clin Proc 74 (1999) 1030-1037
58. Khardori N. Antibiotics-past, present, and future. Med Clin North Am 90 (2006) 1049-1076
59. Marshall W.F., and Blair J.E. Symposium on antimicrobial agents. Part V. The cephalosporins. Mayo Clin Proc 74 (1999) 187-195
60. Hardin T.C., and Jennings T.S. Cefepime. Pharmacotherapy 14 6 (1994) 657-668
61. Yahav D., Paul M., Fraser A., et al. Efficacy and safety of cefepime: s systemic review and meta-analysis. Lancet Infect Dis 7 (2007) 338-348
62. Talan D.A., Moran G.J., and Abrahamian F.M. Severe sepsis and septic shock in the emergency department. Infect Dis Clin N Am 22 (2008) 1-31
63. Abrahamian F.M., Talan D.A., and Moran G.J. Management of skin and soft-tissue infections in the emergency department. Infect Dis Clin N Am 22 (2008) 89-116
64. Abrahamian F.M., Moran G.J., and Talan D.A. Urinary tract infections in the emergency department. Infect Dis Clin N Am 22 (2008) 73-87
65. Fitch M.T., Abrahamian F.M., Moran G.J., et al. Emergency department management of meningitis and encephalitis. Infect Dis Clin N Am 22 (2008) 33-52